Press Release | Thu Oct 3, 2013 2:30am EDT

Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study

* Reuters is not responsible for the content in this press release.